James Peyer Sells 25,000 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sensei Biotherapeutics Price Performance

Shares of SNSE opened at $16.09 on Wednesday. The stock’s 50-day moving average is $26.20 and its two-hundred day moving average is $18.61. The stock has a market cap of $21.56 million, a PE ratio of -0.11 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a 12 month low of $5.60 and a 12 month high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). On average, research analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SNSE. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the first quarter worth about $22,758,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the first quarter worth about $4,188,000. Bank of America Corp DE lifted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Institutional investors and hedge funds own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SNSE. Cantor Fitzgerald began coverage on Sensei Biotherapeutics in a research note on Friday. They set an “overweight” rating on the stock. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a research note on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Leerink Partners began coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics presently has an average rating of “Hold” and an average target price of $46.25.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.